GT Biopharma reported third quarter 2025 results, characterized by reduced R&D expenses and a narrower net loss, driven by decreased production and material costs. The company continues to advance its clinical trials for GTB-3650 and anticipates an IND submission for GTB-5550 in late 2025 or early 2026, while managing its cash position which is expected to fund operations into Q1 2026.
R&D expenses decreased by $0.7 million to $0.6 million in Q3 2025 compared to Q3 2024, primarily due to reduced production and material costs.
positiveNet loss decreased by $0.3 million to $3.1 million in Q3 2025 compared to $3.4 million in Q3 2024, primarily due to decreased R&D expenses.
positiveThe company's Phase 1 trial for GTB-3650 has advanced to Cohort 4, approaching predicted efficacy ranges.
positiveIND submission for GTB-5550 is expected in late December 2025 or January 2026.
positiveCash and cash equivalents were approximately $2.6 million as of September 30, 2025, anticipated to be sufficient to fund operations only into the first quarter of 2026.
attentionSG&A expenses were relatively flat at $2.4 million in Q3 2025 compared to $2.3 million in Q3 2024.
neutralMargin metrics will be available once backend extracts data from insights_json
Encouraged by continued progress of Phase 1 clinical trial for GTB-3650.
Approaching efficacy range predicted by preclinical models for GTB-3650.
Next trial update for GTB-3650 anticipated in Q1 2026.
Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.
Operational metrics provide insight into business drivers and customer engagement beyond traditional financial measures.